Characterization of emergent HIV resistance in treatment-naive subjects enrolled in a vicriviroc phase 2 trial

Journal of Infectious Diseases

Volumn 201, Issue 10, 2010, Pages 1470-1480

  McNicholas, Paul ^a   Wei, Yi ^c   Whitcomb, Jeannette ^b   Greaves, Wayne ^a   Black, Todd A ^a   Tremblay, Cecile L ^c   Strizki, Julie M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; GLYCOPROTEIN P; GLYCOPROTEIN P 160; LAMIVUDINE PLUS ZIDOVUDINE; PLACEBO; UNCLASSIFIED DRUG; VICRIVIROC; VIRUS RNA; 1 ((4,6 DIMETHYL 5 PYRIMIDINYL)CARBONYL) 4 (4 (2 METHOXY 4 (TRIFLUOROMETHYL)PHENYL)ETHYL 3 METHYL 1 PIPERAZINYL) 4 METHYLPIPERIDINE; 1-((4,6-DIMETHYL-5-PYRIMIDINYL)CARBONYL)-4-(4-(2-METHOXY-4-(TRIFLUOROMETHYL)PHENYL)ETHYL-3-METHYL-1-PIPERAZINYL)-4-METHYLPIPERIDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GLYCOPROTEIN GP 160; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CLONAL VARIATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SENSITIVITY; DRUG SUBSTITUTION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION SENSITIVITY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN MOTIF; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS ENVELOPE; VIRUS LOAD; VIRUS RESISTANCE; ANTIVIRAL RESISTANCE; CLASSIFICATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHASE 2 CLINICAL TRIAL;

ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; PIPERAZINES; PYRIMIDINES; RNA, VIRAL; VIRAL LOAD;

EID: 77951884647     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/652189     Document Type: Article

References (23)

1. Brumme ZL, Goodrich J, Mayer HB, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis 2005; 192: 466-474. (Pubitemid 41023125)
2. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HlV-1 infection. J Infect Dis 2005; 191: 866-872. (Pubitemid 40349800)
3. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273: 1856-1862.
4. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-377. (Pubitemid 26272077)
5. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-725.
6. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49: 4911-11919
7. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1 infected, treatmentexperienced patients: AIDS clinical trials group 5211. J Infect Dis 2007; 196: 304-312. (Pubitemid 47047471)
8. Landovitz RJ, Angel JB, Hoffmann C, et al. Phase 11 study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis 2008; 198: 1113-1122.
9. Schurmann D, Fatkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV infected adults. AIDS 2007; 21: 1293-1299. (Pubitemid 46883483)
10. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-4732.
11. Haworth B, Lin H, Fidock M, Dorr P, Strange PG. Allosteric effects of antagonists on signalling by the chemokine receptor CCR5. Biochemical Pharmacology 2007; 74: 891-897. (Pubitemid 47212080)
12. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008; 73: 789-800. (Pubitemid 351397884)
13. Marozsan AJ, Kuhmann SE, Morgan T, et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005; 338: 182-199. (Pubitemid 40835936)
14. Ogert RA, Wojcik L, Buontempo C, et al. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp 120. Virology 2008; 373: 387-399.
15. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81: 2359-2371. (Pubitemid 46303353)
16. Pugach P, Marozsan AJ, Ketas TJ, Landes EL, Moore JP, Kuhmann SE. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007; 361: 212-228. (Pubitemid 46551222)
17. Tsibris AMN, Sagar M, Gulick RM, et al. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008; 82: 8210-8214.
18. Anastassopoulou CG, Ketas TJ, Klasse PJ, Moore JP. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV1 gp41. Proc Natl Acad Sci U S A 2009; 106: 5318-5323.
19. Lu G, Moriyama EN. Vector NTI, a balanced all-in-one sequence analysis suite. Brief Bioinform 2004; 5: 378-388.
20. Kitrinos KM, Amrine-Madsen H, Irlbeck DM, Word JM, Demarest JF. Virologic failure in therapy-naive subjects on aplaviroc plus lopinavirritonavir: detection of aplaviroc resistance requires clonal analysis of envelope. Antimicrob Agents Chemother 2009; 53: 1124-1131.
21. Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002; 54: 323-374.
22. Kuhmann SE, Pugach P, Kunstman KJ, et al. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a smallmolecule CCR5 inhibitor. J Virol 2004; 78: 2790-2807. (Pubitemid 38314338)
23. Trkola A, Kuhmann SE, Strizki JM, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A 2002; 99: 395-400.